Nothing Special   »   [go: up one dir, main page]

UA119458C2 - Сполуки піридину пладієноліду та способи застосування - Google Patents

Сполуки піридину пладієноліду та способи застосування

Info

Publication number
UA119458C2
UA119458C2 UAA201612731A UAA201612731A UA119458C2 UA 119458 C2 UA119458 C2 UA 119458C2 UA A201612731 A UAA201612731 A UA A201612731A UA A201612731 A UAA201612731 A UA A201612731A UA 119458 C2 UA119458 C2 UA 119458C2
Authority
UA
Ukraine
Prior art keywords
methods
pyridine compounds
compounds
pladienolide pyridine
useful
Prior art date
Application number
UAA201612731A
Other languages
English (en)
Inventor
Грегг Ф. Кіні
Грегг Ф. КИНИ
Джон Ванг
Бодуін Герард
Бодуин Герард
Кензо Араі
Кензо Араи
Ксіанг Лі
Ксианг Ли
Гуо Жу Женг
Казунобу Кіра
Казунобу КИРА
Парчарі Тівітмахаісоон
Парчари Тивитмахаисоон
Судіп Праджапаті
Судип ПРАДЖАПАТИ
Ніколас С. Джерхарт
Николас С. Джерхарт
Йошіхіко Котаке
Йошихико Котаке
Сатоші Нагао
Сатоши Нагао
Сонобе Реджіна Канада
Сонобэ Реджина Канада
Масаюкі Міяно
Масаюки МИЯНО
Норіо Мураі
Норио МУРАИ
Сільвія Буонамічі
Сильвия БУОНАМИЧИ
Ліхуа Ю
Лихуа Ю
Юніс Сан Парк
Юнис Сан Парк
Бетті Чан
Бетти Чан
Пітер Дж. Сміт
Питер Дж. СМИТ
Михаел П. Томас
Ерміра Пазоллі
Эрмира Пазолли
Кіан Хуат Лім
Киан Хуат Лим
Original Assignee
Ейсей Р Енд Д Менеджмент Ко., Лтд.
Ейсей Р Энд Д Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA119458(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ейсей Р Енд Д Менеджмент Ко., Лтд., Ейсей Р Энд Д Менеджмент Ко., Лтд. filed Critical Ейсей Р Енд Д Менеджмент Ко., Лтд.
Publication of UA119458C2 publication Critical patent/UA119458C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Даний винахід пропонує нові сполуки пладієноліду піридину, фармацевтичні композиції, що містять такі сполуки, та способи застосування сполук як терапевтичних засобів. Ці сполуки можуть бути корисними у лікуванні раку, зокрема раку, при якому відомо, що корисно застосовувати агенти, які націлені на сплайсосому та мутації в ній. 48
UAA201612731A 2014-05-15 2015-05-13 Сполуки піридину пладієноліду та способи застосування UA119458C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
PCT/US2015/030464 WO2015175594A1 (en) 2014-05-15 2015-05-13 Pladienolide pyridine compounds and methods of use

Publications (1)

Publication Number Publication Date
UA119458C2 true UA119458C2 (uk) 2019-06-25

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201612731A UA119458C2 (uk) 2014-05-15 2015-05-13 Сполуки піридину пладієноліду та способи застосування

Country Status (35)

Country Link
US (1) US9481669B2 (uk)
EP (2) EP3514154B1 (uk)
JP (1) JP6067943B1 (uk)
KR (2) KR102146726B1 (uk)
CN (1) CN107074827B (uk)
AR (1) AR100431A1 (uk)
AU (1) AU2015259237B2 (uk)
BR (1) BR112016026638B1 (uk)
CA (1) CA2947754C (uk)
CL (1) CL2016002835A1 (uk)
CY (1) CY1121550T1 (uk)
DK (1) DK3143016T3 (uk)
ES (1) ES2712401T3 (uk)
HR (1) HRP20190432T1 (uk)
HU (1) HUE041838T2 (uk)
IL (1) IL248529B (uk)
JO (1) JO3668B1 (uk)
LT (1) LT3143016T (uk)
MA (1) MA39915B1 (uk)
ME (1) ME03417B (uk)
MX (2) MX2020004476A (uk)
MY (1) MY195081A (uk)
PE (1) PE20170384A1 (uk)
PH (1) PH12016502249A1 (uk)
PL (1) PL3143016T3 (uk)
PT (1) PT3143016T (uk)
RS (1) RS58400B1 (uk)
RU (1) RU2707730C2 (uk)
SG (1) SG11201609693XA (uk)
SI (1) SI3143016T1 (uk)
TR (1) TR201902328T4 (uk)
TW (1) TWI634115B (uk)
UA (1) UA119458C2 (uk)
WO (1) WO2015175594A1 (uk)
ZA (1) ZA201607354B (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040526A2 (en) 2015-09-01 2017-03-09 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
JP6312282B2 (ja) 2015-11-18 2018-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 固体形態のプラジエノライドピリジン化合物及び使用の方法
CA3056389A1 (en) 2017-03-15 2018-09-20 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
AU2018360559B2 (en) 2017-10-31 2024-08-22 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLXL inhibitors, and BCLXL inhibitors and methods of use
AU2019251096B2 (en) * 2018-04-09 2023-04-20 Eisai R&D Management Co., Ltd. Pladienolide compounds and their use
BR112020020956A2 (pt) * 2018-04-12 2021-03-02 Eisai R&D Management Co., Ltd. derivados de pladienolida como spliceossoma que tem como alvo agentes para tratar câncer
EP3801523B1 (en) * 2018-06-01 2024-09-11 Eisai R&D Management Co., Ltd. Splicing modulators
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
BR112022024833A2 (pt) * 2020-06-05 2023-02-14 Eisai R&D Man Co Ltd Conjugados anticorpo anti-bcma-fármaco e métodos de uso
TW202233187A (zh) 2020-11-04 2022-09-01 日商衛材R&D企管股份有限公司 骨髓發育不良症候群(mds)之生物標記物及其使用方法
WO2022263702A1 (es) * 2021-06-18 2022-12-22 Universidad de Córdoba Compuesto para el tratamiento del glioblastoma
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI311558B (en) 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
CN1671856B (zh) 2002-07-31 2010-05-12 卫材R&D管理株式会社 生理活性物质
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
WO2004050890A1 (ja) 2002-11-29 2004-06-17 Mercian Corporation マクロライド系化合物の製造方法
KR20060110865A (ko) 2003-11-27 2006-10-25 에자이 가부시키가이샤 매크로라이드계 화합물의 수산화에 관여하는 dna
ATE466937T1 (de) 2003-11-28 2010-05-15 Kanagawa Kagaku Gijutsu Akad Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs
US20070199741A1 (en) 2004-07-02 2007-08-30 Kenji Noumi Combined Weighing Apparatus
AU2005265443B2 (en) 2004-07-20 2008-09-04 Eisai R & D Management Co., Ltd DNA coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
EP1935893A4 (en) 2005-10-13 2009-07-22 Eisai R&D Man Co Ltd TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D
US20100021918A1 (en) * 2007-03-05 2010-01-28 Eisai R&D Management Co., Ltd. Method for assaying action of antitumor agent using splicing defects as index
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
PE20170384A1 (es) 2017-05-11
NZ725603A (en) 2023-11-24
AR100431A1 (es) 2016-10-05
US20150329528A1 (en) 2015-11-19
SI3143016T1 (sl) 2019-04-30
BR112016026638B1 (pt) 2022-08-02
KR101710318B1 (ko) 2017-02-24
PT3143016T (pt) 2019-02-27
BR112016026638A2 (uk) 2017-08-15
CN107074827B (zh) 2020-12-18
JP6067943B1 (ja) 2017-01-25
RS58400B1 (sr) 2019-04-30
AU2015259237B2 (en) 2019-08-15
TR201902328T4 (tr) 2019-03-21
HUE041838T2 (hu) 2019-05-28
ME03417B (me) 2020-01-20
CN107074827A (zh) 2017-08-18
SG11201609693XA (en) 2016-12-29
IL248529B (en) 2019-11-28
CL2016002835A1 (es) 2017-04-17
IL248529A0 (en) 2016-12-29
JP2017505282A (ja) 2017-02-16
LT3143016T (lt) 2019-06-10
PH12016502249A1 (en) 2017-02-06
PL3143016T3 (pl) 2019-04-30
WO2015175594A1 (en) 2015-11-19
TWI634115B (zh) 2018-09-01
CY1121550T1 (el) 2020-05-29
KR20160082256A (ko) 2016-07-08
AU2015259237A1 (en) 2016-11-10
RU2019124012A (ru) 2019-08-12
MA39915A (fr) 2017-03-22
MX2020004476A (es) 2021-12-08
MY195081A (en) 2023-01-09
CA2947754A1 (en) 2015-11-19
DK3143016T3 (en) 2019-04-08
EP3514154B1 (en) 2022-08-03
JO3668B1 (ar) 2020-08-27
ZA201607354B (en) 2018-05-30
KR20170021899A (ko) 2017-02-28
HRP20190432T1 (hr) 2019-04-19
RU2016148887A3 (uk) 2018-12-11
TW201625596A (zh) 2016-07-16
EP3514154A1 (en) 2019-07-24
EP3143016B1 (en) 2018-12-12
RU2016148887A (ru) 2018-06-18
NZ764190A (en) 2023-11-24
CA2947754C (en) 2024-01-02
ES2712401T3 (es) 2019-05-13
RU2707730C2 (ru) 2019-11-29
KR102146726B1 (ko) 2020-08-21
US9481669B2 (en) 2016-11-01
MX2016014997A (es) 2017-06-29
EP3143016A1 (en) 2017-03-22
MA39915B1 (fr) 2019-05-31

Similar Documents

Publication Publication Date Title
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
PH12016501791B1 (en) Muscarinic receptor agonists
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2018006155A (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
PH12016501838A1 (en) Compounds and their methods of use
MX2017009608A (es) Compuestos anticancerigenos.
IL255168A0 (en) Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
GB2546703A (en) Compounds